ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it recently provided an educational grant to sponsor the second annual “Chilling at the Beach─Therapeutic Hypothermia and Temperature Management: Current and Future Directions” conference hosted by the University of Miami Miller School of Medicine.
During the two-day meeting, key thought leaders from around the world representing multiple specialities convened to discuss when therapeutic hypothermia is most appropriate to use and under what conditions temperature management is helpful for various indications.
The lectures and roundtable discussions attracted an international audience from pediatrics, nursing, cardiology, neurology, intensivists, surgeons, and emergency care physicians representing specialites such as acute myocardial infarction, sudden cardiac arrest, burn, surgery, neuro fever, and stroke. They came to learn about the latest temperature management science ranging from anti-shivering protocols to managing complications onto temperature management in emerging areas such as pediatric cardiac surgery and hypothermia for organ transplantation.
According to Course Director W. Dalton Dietrich, III, PhD, Scientific Director, the Miami Project to Cure Paralysis and Professor of Neurological Surgery, University of Miami Miller School of Medicine, the four conference tracks offered discussions on ICU and intra-operative temperature management, temperature management strategies, the future of temperature management, and bench-to-bedside cooling strategies.
“The 2012 Chilling at the Beach Miami Conference attracted over 130 attendees who discussed and debated a wide range of temperature related topics important to the critical care of patients with acute and chronic injuries. The significance of this year’s conference is that clinicians, critical care nurses, and scientists from many diverse specialties gathered at one conference to learn and discuss the benefits of temperature management and therapeutic hypothermia for a widening range of indications,” said Dr. Dietrich. “The fields of post-cardiac arrest, head trauma, acute spinal injury, stroke, seizures, and organ transplantation were well-represented at the conference.”
“Temperature management is emerging as a standard of care for advancing critical care and improving outcomes in a range of life-altering situations,” said James Palazzolo, President of ZOLL Sunnyvale (Calif.) operations. “The conference afforded attendees the opportunity to evaluate a variety of cooling techniques, including intravascular, and the role they play in improving outcomes.”
The next “Chilling at the Beach” therapeutic hypothermia and temperature management conference for which ZOLL is providing an educational grant is to the University of Innsbruck. That symposia is scheduled for June 7-9 in Portoroz, Slovenia.
About ZOLL IVTM
ZOLL’s Intravascular Temperature Management (IVTM™) system provides cooling and warming from a catheter inserted into a patient’s vein. This provides better control of the core body temperature by directly cooling or warming the patient’s blood as it flows through the body. This catheter is connected to the Thermogard XP® console, which when used to induce hypothermia, circulates ice-cold saline solution inside a balloon catheter. After a period of therapeutic hypothermia, typically 12-24 hours, the system slowly and accurately rewarms the patient back to normal body temperature. Since the saline flows only within the catheter, no fluid is infused into the patient. The ZOLL IVTM system is efficient, precise and easy to use, and frees up clinical staff to attend to other patient needs.
ZOLL IVTM offers a variety of catheters with placement options to handle specific patient challenges. Options for catheter placement include femoral, subclavian, and internal jugular.
About ZOLL Medical Corporation
ZOLL Medical Corporation (zoll.com) develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.
A NASDAQ Global Select company and a three-time Forbes 100 Most Trustworthy Company, ZOLL was designated in 2011 as one of Forbes Top 100 Small Public Companies in America with annual revenues under $1 billion. ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe.
Certain statements contained in this press release, including statements regarding the anticipated development of the Company's business, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K filed with the SEC on November 23, 2011, as updated by the Company’s subsequent SEC filings, including Quarterly Reports on Form 10-Q. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.
Copyright © 2012 ZOLL Medical Corporation. All rights reserved. IVTM and ZOLL are trademarks and/or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. All trademarks are the property of their respective owners.
ZOLL Medical Corporation Investor Contact:
A. Ernest Whiton, Chief Financial Officer
P: +1 978-421-9655